» Articles » PMID: 32348723

Platelet Factor 4 Interactions with Short Heparin Oligomers: Implications for Folding and Assembly

Overview
Journal Biophys J
Publisher Cell Press
Specialty Biophysics
Date 2020 Apr 30
PMID 32348723
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Association of platelet factor 4 (PF4) with heparin is a first step in formation of aggregates implicated in the development of heparin-induced thrombocytopenia (HIT), a potentially fatal immune disorder affecting 1-5% of patients receiving heparin. Despite being a critically important element in HIT etiology, relatively little is known about the specific molecular mechanism of PF4-heparin interactions. This work uses native mass spectrometry to investigate PF4 interactions with relatively short heparin chains (up to decasaccharides). The protein is shown to be remarkably unstable at physiological ionic strength in the absence of polyanions; only monomeric species are observed, and the extent of multiple charging of corresponding ions indicates a partial loss of conformational integrity. The tetramer signal remains at or below the detection threshold in the mass spectra until the solution's ionic strength is elevated well above the physiological level, highlighting the destabilizing role played by electrostatic interactions vis-à-vis quaternary structure of this high-pI protein. The tetramer assembly is dramatically facilitated by relatively short polyanions (synthetic heparin-mimetic pentasaccharide), with the majority of the protein molecules existing in the tetrameric state even at physiological ionic strength. Each tetramer accommodates up to six pentasaccharides, with at least three such ligands required to guarantee the higher-order structure integrity. Similar results are obtained for PF4 association with longer and structurally heterogeneous heparin oligomers (decamers). These longer polyanions can also induce PF4 dimer assembly when bound to the protein in relatively low numbers, lending support to a model of PF4/heparin interaction in which the latter wraps around the protein, making contacts with multiple subunits. Taken together, these results provide a more nuanced picture of PF4-glycosaminoglycan interactions leading to complex formation. This work also advocates for a greater utilization of native mass spectrometry in elucidating molecular mechanisms underlying HIT, as well as other physiological processes driven by electrostatic interactions.

Citing Articles

Serglycin controls megakaryocyte retention of platelet factor 4 and influences megakaryocyte fate in bone marrow.

Lykins J, Becker I, Camacho V, Alfar H, Park J, Italiano J Blood Adv. 2024; 9(1):15-28.

PMID: 38941534 PMC: 11732581. DOI: 10.1182/bloodadvances.2024012995.


Molecular architecture and platelet-activating properties of small immune complexes assembled on heparin and platelet factor 4.

Yang Y, Du Y, Ivanov D, Niu C, Clare R, Smith J Commun Biol. 2024; 7(1):308.

PMID: 38467823 PMC: 10928113. DOI: 10.1038/s42003-024-05982-4.


Assessing Genetic Algorithm-Based Docking Protocols for Prediction of Heparin Oligosaccharide Binding Geometries onto Proteins.

Holmes S, Desai U Biomolecules. 2023; 13(11).

PMID: 38002315 PMC: 10669598. DOI: 10.3390/biom13111633.


Mass spectrometry-based methods to characterize highly heterogeneous biopharmaceuticals, vaccines, and nonbiological complex drugs at the intact-mass level.

Kaltashov I, Ivanov D, Yang Y Mass Spectrom Rev. 2022; 43(1):139-165.

PMID: 36582075 PMC: 10307928. DOI: 10.1002/mas.21829.


Solution- and gas-phase behavior of decavanadate: implications for mass spectrometric analysis of redox-active polyoxidometalates.

Favre D, Bobst C, Eyles S, Murakami H, Crans D, Kaltashov I Inorg Chem Front. 2022; 9(7):1556-1564.

PMID: 35756945 PMC: 9216222. DOI: 10.1039/d1qi01618k.


References
1.
Huynh A, Arnold D, Moore J, Smith J, Kelton J, Nazy I . Development of a high-yield expression and purification system for platelet factor 4. Platelets. 2017; 29(3):249-256. DOI: 10.1080/09537104.2017.1378808. View

2.
Woulfe D, Lilliendahl J, August S, Rauova L, Kowalska M, Abrink M . Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice. Blood. 2007; 111(7):3458-67. PMC: 2275015. DOI: 10.1182/blood-2007-07-104703. View

3.
Zong C, Huang R, Condac E, Chiu Y, Xiao W, Li X . Integrated Approach to Identify Heparan Sulfate Ligand Requirements of Robo1. J Am Chem Soc. 2016; 138(39):13059-13067. PMC: 5068570. DOI: 10.1021/jacs.6b08161. View

4.
Bertini S, Fareed J, Madaschi L, Risi G, Torri G, Naggi A . Characterization of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential. Clin Appl Thromb Hemost. 2017; 23(7):725-734. DOI: 10.1177/1076029616685430. View

5.
Imberty A, Lortat-Jacob H, Perez S . Structural view of glycosaminoglycan-protein interactions. Carbohydr Res. 2007; 342(3-4):430-9. DOI: 10.1016/j.carres.2006.12.019. View